Krystal Biotech, Inc. (KRYS)
NASDAQ: KRYS · Real-Time Price · USD
234.13
+12.17 (5.48%)
At close: Dec 5, 2025, 4:00 PM EST
235.00
+0.87 (0.37%)
After-hours: Dec 5, 2025, 7:58 PM EST
Krystal Biotech Employees
Krystal Biotech had 275 employees as of December 31, 2024. The number of employees increased by 46 or 20.09% compared to the previous year.
Employees
275
Change (1Y)
46
Growth (1Y)
20.09%
Revenue / Employee
$1,356,960
Profits / Employee
$723,309
Market Cap
6.79B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
KRYS News
- 9 days ago - Krystal Biotech to Present at 8th Annual Evercore Healthcare Conference - GlobeNewsWire
- 19 days ago - Krystal Biotech: Vyjuvek Gene Therapy Well Positioned For Growth - Seeking Alpha
- 4 weeks ago - Krystal's Q3: Platform Designation Adds Pipeline Leverage As Vyjuvek Scales (Rating Upgrade) - Seeking Alpha
- 4 weeks ago - Krystal Biotech, Inc. (KRYS) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - FDA Expands Krystal Biotech Vyjuvek's Label Allowing Newborns Access To Gene Therapy For Blistering Skin - Benzinga
- 2 months ago - Krystal Biotech Announces FDA Approval of Updated VYJUVEK® Label - GlobeNewsWire
- 3 months ago - Krystal Biotech: A "Strong Buy" Despite KB707 Melanoma Tumor Targeting Update - Seeking Alpha
- 3 months ago - Krystal Biotech Announces Update on Development Plans for Oncology Program KB707 and Prioritization of Inhaled KB707 for the Treatment of Non-Small Cell Lung Cancer - GlobeNewsWire